Paul Hallenbeck

Paul Hallenbeck is a Senior Biopharmaceutical Research and Development Executive and Entrepreneur with 25 years of experience in the biotechnology industry.

His expertise covers all phases of oncology drug discovery, development, and translation to clinical trials, focusing on complex targeted biologics and innovative therapeutic compounds.

He has a quality record of identifying scientific, medical, and business opportunities, licensing, developing and implementing strategic plans, financing, and managing biotechnology companies and programs.

Paul excels in designing, executing, and interpreting clinical research programs for successful transitions from candidate drug selection to development phases, including regulatory submissions.

He is skilled in building, motivating, managing, developing, and leading multi-disciplinary, cross-cultural teams in a cost-effective and expeditious manner.

Paul Hallenbeck is a published author, patent holder, and multiple award winner with a strong presence in scientific and regulatory circles.

He is an articulate public speaker with numerous publications, patents, and presentations at Pharma, Biotech, FDA, Board, and VC investor meetings.

Paul holds a B.Sc. in Chemistry from Siena College and a Ph.D. in Microbiology from the University of Illinois at Urbana-Champaign.

He has held key positions in various organizations including Founder and Chief Executive Officer at Seneca Therapeutics, Inc., Executive Director at Premier Research, and Chief Scientific Officer at Hangzhou Bensheng Pharmaceuticals.

Paul has also been involved with several biotechnology companies where he held roles like President, CEO, Founder, Program Head, and Chief Scientific Officer.